Skip to Main Content

Good morning, everyone, and how are you today? We are doing just fine, thank you, especially now that rain clouds have departed and the sun is trying mightily to warm the otherwise damp and chilly Pharmalot campus. Such circumstances call, not surprisingly, for a hot cup or three of stimulation. And so we are firing up the coffee kettle. Our choice remains mocha nut fudge, since we have an unusually large stash. We generally keep a year’s supply of each flavor, in case you were wondering. Anyway, time to get cracking. Here are your tidbits. Hope you conquer the world today and do keep in touch. …

Novartis (NVS) chief executive Vas Narasimhan says the company plans to price a forthcoming gene therapy for spinal muscular atrophy “far lower” than the $4 million to $5 million figure the drug maker has said it could be worth, Reuters writes. U.S. regulators are expected to make a decision this month on whether to approve Zolgensma, a one-time therapy seen as a potential long-term solution for the rare disease that is the leading genetic cause of death in infants. The company has previously said it could price the treatment in a range of $1.5 million to $5 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!